SOLICITATION NOTICE
Q -- Genetic Screening of Interactions of wild type and mutant proteins with humans who have neurological abnormalities
- Notice Date
- 6/10/2013
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-CSB-(HG)-2013-179-DLM
- Archive Date
- 7/2/2013
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- INTRODUCTION: THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) on behalf of the National Human Genome Research Institute, (NHGRI), intends to negotiate and award a purchase order on a non-competitive sole source basis to University of Miami Health System, Miller School of Medicine, University of Miami, 1600 NW 10th Avenue, Room 6079, Miami, Florida 33136 to provide a comprehensive and validated list of statistically significant interacting genes in S. pombe and in S. cerevisiae that potentially regulate the activity of six genes for the Undiagnosed Diseases program. Procurement : • The Contractor shall provide a phenotypic assessment of wild-type or mutant protein in S. pombe to provide evidence that the mutation alters a specific aspect of the wild-type protein function. • The Contractor shall provide a comprehensive and validated list of statistically significant interacting genes in S. pombe and in S. cerevisiae that potentially regulate the activity of the genes in question. • The Contractor shall provide bioinformatics analysis and interpretation of the genetic screen results using Metasearch of PubMed, searches of STRING, analysis of interactions through GEM.APP and related sites, and identification of phenologs. • The Contractor shall provide unique services specific to genes suspected of causing neurological disease to meet the program goals of the UDP. • The Contractor's turn-around-time for UDP to receive results will be 1.2 months once the initial validation is completed. • The Contractor shall supply electronic copies of all reports appropriate for deposition in the UDP process management system and for other collaborations. BACKGROUND : The National Institutes of Health (NIH) is the nation's leading medical research agency and the primary Federal agency conducting and supporting medical discoveries that improve people's health and save lives. The National Institute of Health (NIH), is a trans-National Institutes of Health (NIH) initiative that focuses on the most puzzling medical cases referred to the NIH Clinical Center in Bethesda, MD. It was organized by the National Human Genome Research Institute (NHGRI), the NIH Office of Rare Diseases Research (ORDR), and the NIH Clinical Center. Many medical specialties from other NIH research centers and institutes contribute the expertise needed to conduct the program, including endocrinology, immunology, oncology, dermatology, dentistry, cardiology and genetics, among the dozens of participating senior attending physicians. The goals of the UDP include providing answers to patients with mysterious conditions that have long eluded diagnosis and to advance medical knowledge about rare and common diseases. The UDP was established to evaluate participants who have undiagnosed medical conditions. UDP participants have generally received extensive diagnostic workups before traveling to NIH and often have numerous and/or complex medical problems. The UDP program makes use of a diverse set of diagnostic and research techniques both to attempt to find a diagnosis and to generate research projects to advance medical knowledge. UDP laboratory supports the research needs of the UDP by collaborating on clinically identified new and rare neurological diseases. PERIOD OF PERFORMANCE : June 2013 through October 2013 PROJECT DESCRIPTION: The DIR-NHGRI- Undiagnosed Diseases program (UDP) protocol 76-HG-0238, Clinical Trial Number: NCT00369421 are connected to this testing, which began in 2008 as a vehicle for admitting patients with broader range of inborn errors of metabolism. Under this observational protocol study, the Researchers in the Protocol study intend on diagnosing and treating certain inborn errors of metabolism. By doing this, researchers hope to expand their knowledge about these disorders and provide access to patients of interest for research, teaching, and clinical experience. Patients enrolled in this protocol have been referred with a known or suspected inborn error of metabolism, heritable disorder, or genetic predisposition. Patients participating in this study will be examined and treated on an outpatient basis, if practical. However, patients requiring specialized tests or treatments will be admitted to the NIH Clinical Center as necessary. Researchers will use only accepted medical procedures in diagnosing (medical history, physical examinations, X-ray studies, eye examinations, blood tests, and urine tests) and treating the patients involved in this study. Additional tests may be required on a case by case basis. UDP has a critical need to develop collaborations with Miami University School of Medicine to define the function of genes in causing neurological disease. Contractor Requirements : 1. The Contractor shall provide a phenotypic assessment of wild-type or mutant protein in S. pombe to provide evidence that the mutation alters a specific aspect of the wild-type protein function. 2. The Contractor shall provide a comprehensive and validated list of statistically significant interacting genes in S. pombe and in S. cerevisiae that potentially regulate the activity of the genes in question. 3. The Contractor shall provide bioinformatics analysis and interpretation of the genetic screen results using Metasearch of PubMed, searches of STRING, analysis of interactions through GEM.APP and related sites, and identification of phenologs. 4. The Contractor shall provide unique services specific to genes suspected of causing neurological disease to meet the program goals of the UDP. 5. The Contractor's turn-around-time for UDP to receive results will be 1.2 months once the initial validation is completed. 6. The Contractor shall supply electronic copies of all reports appropriate for deposition in the UDP process management system and for other collaborations. B. Desired Results/Functions/End Items : 1. Test results with qualified interpretations in a timely way given the requirements of the particular test. 2. Research collaborations will be conducted via Videoconferences, email communications, shared professional presentations, posters and publications. Grand Round presentations at the Contractor's location and the NIH Clinical Center may also occur. C. Technical Specifications/Standards/Methods: 1. The Contractor shall supply results with qualified interpretations in formats appropriate to the exome analysis pipeline and process management systems. D. Special Handling or Handling Requirements : 1. The Contractor shall provide result reports and record methods and materials as appropriate to the highest scientific standards. These materials, methods and results will be shared will agreed upon UDP collaborators. E. The Government will provide to the Contractor : 1. The Government will not furnish any government property to the vendor 2. The Government will provide plasmids of the wild type and mutant cDNAs for the genes to be investigated. 3. The Government will send all plasmids via Fed-Ex overnight to the Contractor for testing. 4. The Government will not furnish any facilities to be used by the vendor. The Government will be responsible for reviewing and approving reports and similar matters generated : 1. Results will be provided electronically to the UDP via secure email, the UDP ftp site or direct deposition into the UDP process management system. 2. Results will also be shared with UDP collaborators as defined mutually. F. Reporting Requirements and Deliverables : 1. The Government will receive all electronic results within 3.6 months of the Contractor receiving the plasmids. 2. The Government will receive additional reports for any test added-on after the Contractor receives the original specimen. REGULATORY AUTHORITY: This acquisition is conducted under the authority of the Federal Acquisition Regulations (FAR) Subpart 13.106-1(b) Soliciting from a single source, only one responsible source and no other supplies or services will satisfy agency requirements. ADDITIONAL INFORMATION: Industry Classification (NAICS) Code is 541712, Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology), and the Small Business Size Standard is 500. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001). The resultant Contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-66 (April 1, 2013). This requirement is under the SAT of $150,000.00. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. This notice of intent is not a request for competitive proposals. Inquiries to this announcement, referencing synopsis number NHLBI-CSB-(HG)-2013-179-DLM, may be submitted to the National, Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses to this notice shall contain sufficient documentation to establish the interested parties' bona-fide capabilities for fulfilling the requirement. Responses will only be accepted if dated and signed by an authorized company representative. Note: In order to receive an award from NIH/NHLBI, contractors must be registered and have a valid CCR and ORCA on-line at https://www.sam.gov/portal/public/SAM/.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-CSB-(HG)-2013-179-DLM/listing.html)
- Place of Performance
- Address: NIH, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN03085376-W 20130612/130611000929-c6fd8a2fa9b91b3b7b9e41c92b577e3a (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |